Dec+5+Agenda+Notes

Welcome to DNA Vaccines 2012 David B. Weiner, PhD Professor, University of Pennsylvania //helped found the field of DNA vaccines. Focuses on HIV//

//The Future of Malaria Vaccines// //Chairs: Ashley Birkett & Niranjan Sardesai// //Ashley is a guy from UK working on Malaria vaccines// ///*// //Niranjan Sardesai// //Cheif operating officer of Inovio Pharmaceutical; they make synco vaccines; working on universal flu vaccines among other things// //*///

//9:30 AM - 10:00 AM// //**Robust CD8+ T-Cell-Dependent IFN-Gamma Responses Against Restricted Domains on P. Falciparum Antigens Induced by a DNA- Prime-Adenovector Boost Vaccine Regimen are Associated with Protection Against Sporozoite Challenge**// Martha Sedegah, PhD //Senior Scientist & Director, Clinical Immunology Malaria Program, Navy Component, U. S. Military Malaria Vaccine Program//

//10:00 AM - 10:30 AM// //From the Bench to the Clinic: Development of Viral Vector-Based Blood-Stage Malaria Vaccines// //Sumi Biswas, DPhil// //Group Leader/Post Doctoral Scientist, The Jenner Institute// //located in at Oxford//

//Frontiers in Vaccine Research// //Chairs: Matti Sällberg & Martha Sedegah// ///*// //Matti Sällberg// //focuses on hepatotropic viruses; from the Karolinska Institute in Sweden// //Martha was already on agenda// //*///

//11:00 AM - 11:30 AM// //Therapeutic Indications for DNA Vaccines// //Tony Ford Hutchinson, PhD// //President, Ford-Hutchinson Consulting Ltd// //located in Pennsylvania//

//11:30 AM - 12:00 PM// //**What is the Role of Therapeutic Vaccination in the Era of Directly Acting Antivirals in the Therapy of Hepatitis C**// Matti Sällberg, PhD //Board Member & Consultant, Tripep AB// //Professor, Karolinska Institutet//

//12:00 PM - 12:30 PM// //Tuberculosis Vaccines// //David Hokey, PhD// //Director of Immunology, Aeras// //in Maryland. Aeras produces many constructs, assesses the immune response induced by candidate vaccines//

//Cutting Edge RNA Technologies// //Chairs: Peter Liljeström & Andrew Geall// //Peter Liljeström from Karolinska Institute in Sweden//

//Andrew Geall// //RNA Vaccine Platform Leader at Novartis// //Novartis is a Swiss multinational pharmaceutical company//

//1:45 PM - 2:10 PM// //DNA/RNA Replicon Vaccines// //Peter Liljeström, PhD// //Professor of Infectious Disease Control, Karolinska Institutet//

//A Replicon in genetics is a region of DNA or RNA, that replicates from a single origin of replication.//

//2:10 PM - 2:35 PM// //Non-Viral Delivery of Self-Amplifying RNA Vaccines// //Andrew Geall, PhD// //RNA Vaccine Platform Technology Leader, Novartis Vaccines & Diagnostics//

//2:35 PM - 3:00 PM// //Development of Therapeutic and Prophylactic Vaccines// //Karl-Josef Kallen, MD, PhD// //Chief Scientific & Chief Medical Officer, CureVac GmbH// //CureVac slogan (the RNA people)// //uses medical potential of messenger RNA// //located in Tubingen Germany// //gmbh is a german acronym that translates to a company with limited liability//

//Abstract Session// //Chairs: Anne De Groot & Amir Khan//

//Anne De Groot// //expert in epitope driven vaccines at Brown University (at Providence Rhode Island)// //she is also CEO of EpiVax//

//Amir Khan// //an epidemiologist based in Karachi Pakistan// //Aamir is an Associate at the Johns Hopkins Bloomberg School of Public Health and an Adjunct Associate Professor of Global Health at the University of Texas Health Science Center.// //Founder and Executive Director of IRD (interactive research and development or something that works in poorer countries)// //Aamir directs the Indus Hospital’s//

//3:30 PM - 3:45 PM// //A Multi-agent Encephalitic Alphavirus DNA Vaccine Delivered by Electroporation Elicits Protective Immunity against Aerosol Challenge with Eastern and Western Equine Encephalitis Viruses in Nonhuman Primates// //Drew Hannaman - Vice President, Ichor Medical Systems, Inc.// //Ichor is located in San Diego California//

//3:45 PM - 4:00 PM// //Inducing Potent Humoral and Cellular Responses to Multiple Sporozoite and Liver-Stage Malaria Antigens Using pDNA// //Bernadette Ferraro, PhD, MPH// //Postdoctoral Fellow, University of Pennsylvania// //Ferraro may be a Portuguese name//

//4:00 PM - 4:15 PM// //Development of a Novel DNA Vaccine Strategy for Prevention of Clostridium Difficile Infection// //Michele A. Kutzler, PhD// //Assistant Professor, Drexel University College of Medicine// //located in Philadelphia//

//4:15 PM - 4:30 PM// //NF-ĸB Activation Mediates Tumor-Specific CTL Responses Elicited by DNA Vaccines// //Maarten Ligtenberg// //PhD Candidate, Karolinska Institutet// //located in Sweden//

//4:30 PM - 5:30 PM// //**Plenary Roundtable I - Chairs: John Sterling & David Weiner Development and Commercialization of Novel Vaccines**// Ashley Birkett Tony Ford Hutchinson Niranjan Sardesai Jeffrey Ulmer//

Jeffrey Ulmer Global Head, External Research at Novartis